The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
N | Nervous system | |
2
|
N07 | Other nervous system drugs | |
3
|
N07C | Antivertigo preparations | |
4
|
N07CA | Antivertigo preparations | |
5
|
N07CA01 | Betahistine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| ORAL | Oral | 24 mg |
| Active Ingredient |
|---|
|
Betahistine dihydrochloride is a histamine-like drug in which pharmacological activity can be attributed to a specific effects and/or more direct influences on recovery mechanisms the vestibular nuclei. It has weak agonist activity at histamine H1 receptors and moderate antagonist activity at H3 receptors. Betahistine may increase blood flow to the cochlear region as well as to the whole brain. |
| Document | Type | Information Source | |
|---|---|---|---|
| ALFINOR Tablet | MPI, EU: SmPC | Υπουργείο Υγείας (CY) | |
| BETA-SYNTO Tablet | MPI, EU: SmPC | Υπουργείο Υγείας (CY) | |
| SERC Tablet | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) | |
| TREVIGO Tablet | MPI, Generic | Marketing Authorisation Holder | |
| VERTIMED Tablet | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.